Biotech VC Funding Rises As Fewer Companies Get More Dollars

Public company valuations continue to slide as stock market investors shift priorities, but private biotechnology firms are attracting near record-breaking levels of venture capital with one pretty important caveat: More money is being invested in fewer US companies, especially at the earliest stages of business formation.

The $1.81bn in venture capital invested in US biotech firms during the first quarter of 2016 was the sixth highest quarterly total ever, but with 118 companies raising VC cash, it was far from the highest number of deals in any given quarter, according to the MoneyTree Report from the National Venture Capital Association (NVCA) and PricewaterhouseCoopers based on Thomson Reuters data that goes back to 1995. And despite the large dollar volume raised by biotechs during the first three months of this year, only $359.1m was labeled as a "first sequence" investment, which was lower than any quarter in 2015.

Some recently funded biotech companies illustrate the focus of a lot of venture capital these days: big Series A and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Stock Watch: Sanofi And Merck Temper Big Pharma Q2 Earnings Cheer

 
• By 

The investor enthusiasm that greeted initial second-quarter pharma earnings announcements was dampened by the results from Sanofi and Merck & Co. Sanofi was particularly punished by investors despite overall growth, while Merck’s revenue fall was probably baked into expectations.

Japan Results Roundup: Reduced Forex Impact, Uncertain US Tariff Outlook

 
• By 

Most major Japanese firms report generally positive fiscal first quarter results, led by mainstay growth and despite lower currency effects. But the future impact of any US pharma tariffs remains an overhang.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.

S&E In Brief: Launch Updates And Political Headwinds

 

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.

More from Scrip

S&E In Brief: Launch Updates And Political Headwinds

 

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.

Another Day Another Win For Novartis’s Ianalumab – This Time In ITP

 
• By 

The Swiss drugmaker’s BAFF-R inhibitor and ADCC-mediated B-cell depletor candidate has chalked up another win in late-stage development, further strengthening its pipeline-in-a-product bid.

Pfizer/Astellas’s Padcev Scores First Big Win In Bladder Cancer Study

 

The drug, combined with Merck’s Keytruda, was successful among certain chemotherapy-ineligible MIBC patients, with another Phase III readout expected by March 2026.